dalteparin has been researched along with Local Neoplasm Recurrence in 9 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study." | 9.41 | Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021) |
| "We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study." | 5.41 | Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021) |
| "Compared to cancer patients with symptomatic VTE, those with incidental VTE have different clinical features at presentation, with a numerically lower incidence of recurrent VTE and a numerically higher incidence of major bleeding." | 3.01 | Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. ( Agnelli, G; Bauersachs, R; Becattini, C; Cohen, AT; Connors, JM; Dentali, F; Falvo, N; Giustozzi, M; Huisman, M; Ruperez Blanco, AB; Szmit, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Groen, HJM | 1 |
| van der Heijden, EHFM | 1 |
| Klinkenberg, TJ | 1 |
| Biesma, B | 1 |
| Aerts, J | 1 |
| Verhagen, A | 1 |
| Kloosterziel, C | 1 |
| Pieterman, R | 1 |
| van den Borne, B | 1 |
| Smit, HJM | 1 |
| Hoekstra, O | 1 |
| Schramel, FMNH | 1 |
| van der Noort, V | 1 |
| van Tinteren, H | 1 |
| Smit, EF | 1 |
| Dingemans, AC | 1 |
| Cook, C | 1 |
| Callaway, M | 1 |
| McBane, RD | 1 |
| Wysokinski, WE | 1 |
| Le-Rademacher, JG | 1 |
| Zemla, T | 1 |
| Ashrani, A | 1 |
| Tafur, A | 1 |
| Perepu, U | 1 |
| Anderson, D | 1 |
| Gundabolu, K | 1 |
| Kuzma, C | 1 |
| Perez Botero, J | 1 |
| Leon Ferre, RA | 1 |
| Henkin, S | 1 |
| Lenz, CJ | 1 |
| Houghton, DE | 1 |
| Vishnu, P | 1 |
| Loprinzi, CL | 1 |
| Mulder, FI | 1 |
| Di Nisio, M | 1 |
| Ay, C | 1 |
| Carrier, M | 2 |
| Bosch, FTM | 1 |
| Segers, A | 1 |
| Kraaijpoel, N | 1 |
| Grosso, MA | 1 |
| Zhang, G | 1 |
| Verhamme, P | 1 |
| Wang, TF | 1 |
| Weitz, JI | 1 |
| Middeldorp, S | 1 |
| Raskob, G | 1 |
| Beenen, LFM | 1 |
| Büller, HR | 1 |
| van Es, N | 1 |
| Park, JY | 1 |
| Verso, M | 1 |
| Munoz, A | 1 |
| Bauersachs, R | 2 |
| Huisman, MV | 1 |
| Mandalà, M | 1 |
| Vescovo, G | 1 |
| Becattini, C | 2 |
| Agnelli, G | 2 |
| Giustozzi, M | 1 |
| Connors, JM | 1 |
| Ruperez Blanco, AB | 1 |
| Szmit, S | 1 |
| Falvo, N | 1 |
| Cohen, AT | 1 |
| Huisman, M | 1 |
| Dentali, F | 1 |
| Auer, RC | 1 |
| Ott, M | 1 |
| Karanicolas, P | 1 |
| Brackstone, MR | 1 |
| Ashamalla, S | 1 |
| Weaver, J | 1 |
| Tagalakis, V | 1 |
| Boutros, M | 1 |
| Stotland, P | 1 |
| Marulanda, AC | 1 |
| Moloo, H | 1 |
| Jayaraman, S | 1 |
| Patel, S | 1 |
| Le Gal, G | 1 |
| Spadafora, S | 1 |
| MacLellan, S | 1 |
| Trottier, D | 1 |
| Jonker, D | 1 |
| Asmis, T | 1 |
| Mallick, R | 1 |
| Pecarskie, A | 1 |
| Ramsay, T | 1 |
| Koczorek, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-07-03 | Recruiting | ||
| A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism[NCT02585713] | Phase 3 | 300 participants (Actual) | Interventional | 2015-11-20 | Completed | ||
| Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study[NCT03045406] | Phase 3 | 1,168 participants (Actual) | Interventional | 2017-04-13 | Active, not recruiting | ||
| A Multicentre Randomized Controlled Trial of the Use of Extended Peri-Operative Low Molecular Weight Heparin to Improve Cancer Specific Survival Following Surgical Resection of Colorectal Cancer[NCT01455831] | Phase 3 | 616 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The rate (percentage) of patients experiencing major bleeding at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Apixaban) | 0 |
| Arm B (Dalteparin) | 2.1 |
A similar analysis as described for the primary safety analysis will be used. The rate (percentage) of patients experiencing major bleeding or a clinically relevant non-major bleed at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A (Apixaban) | 7.0 |
| Arm B (Dalteparin) | 8.1 |
Analyzed using the same methods described above for the primary endpoint.Time to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) is defined as the time from randomization to the date the patient experienced the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE). (NCT02585713)
Timeframe: Up to 3 months post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A (Apixaban) | NA |
| Arm B (Dalteparin) | NA |
6 trials available for dalteparin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2019 |
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outc | 2020 |
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outc | 2020 |
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outc | 2020 |
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Pyrazoles; Pyridones; Treatment Outc | 2020 |
Clinical implications of incidental venous thromboembolism in cancer patients.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Venous Thromb | 2020 |
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Drug Therapy, Comb | 2021 |
Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasm Recurrence, Local; Neoplasms; Venous Thromb | 2021 |
Efficacy and safety of extended duration to perioperative thromboprophylaxis with low molecular weight heparin on disease-free survival after surgical resection of colorectal cancer (PERIOP-01): multicentre, open label, randomised controlled trial.
Topics: Adolescent; Adult; Anticoagulants; Colorectal Neoplasms; Disease-Free Survival; Heparin, Low-Molecul | 2022 |
3 other studies available for dalteparin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Low molecular weight heparin and the risk of haemorrhage following percutaneous biopsy, despite a normal standard clotting screen.
Topics: Aged; Biopsy, Needle; Carcinoma, Endometrioid; Enoxaparin; Female; Hemorrhage; Humans; Iliac Vein; I | 2001 |
The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer.
Topics: Anticoagulants; Dalteparin; Female; Humans; Neoplasm Recurrence, Local; Rivaroxaban; Venous Thromboe | 2020 |
[Long-term treatment of venous thromboembolism and prevention of relapse in cancer patients].
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasm Recurrence, Loc | 2015 |